Document:

Exhibit 10.1 

SECURITIES PURCHASE
AGREEMENT

THIS SECURITIES
PURCHASE AGREEMENT (the “Agreement”) is made as of the 7th day of October, 2014
by and between Bioheart, Inc., a Florida corporation (the “Company”), and Magna Equities II, LLC, a New
York limited liability company (the “Investor”).

WHEREAS,
the Investor is willing to lend the Company $205,000, which loan is evidenced by a promissory note, in substantially the form attached
hereto as Exhibit A (the “Note”), which is convertible into shares of the Company’s common
stock, $0.001 par value (the “Common Stock”), in accordance with the terms of this Agreement and such
Note;

WHEREAS,
upon the terms and condition stated in the Agreement and pursuant to Section 4(a)(2) of the 1933 Act (as defined below) and Rule
506 of Regulation D promulgated thereunder, the Investor wishes to purchase, and the Company wishes to sell, the Note with the
principal amount equal to $307,500 (the shares of Common Stock issuable upon conversion of the Note, collectively, the “Conversion
Shares”). The Note, together with the Conversion Shares, are referred to herein as the “Securities”
and the offering contemplated hereby is referred to herein as the “Offering”;

WHEREAS,
the parties have agreed that the obligation to repay the Note shall be an unsecured obligation of the Company; and

WHEREAS,
at the Closing (as defined below), the parties hereto shall execute and deliver a Registration Rights Agreement, in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company has agreed
to provide certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement),
under the 1933 Act (as defined below) and the rules and regulations promulgated thereunder, and applicable state securities laws.

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the
premises and the mutual agreements, representations and warranties, provisions and covenants contained herein, the parties hereto,
intending to be legally bound hereby, agree as follows:

1.                 
Purchase and Sale of Note. On the Closing Date (as hereinafter defined), subject to the terms and conditions of this
Agreement, the Investor hereby agrees to purchase, and the Company hereby agrees to sell and issue, a Note in the principal amount
of $307,500 (the “Principal Amount”).

2.                 
Purchase Price. The purchase price for the Note to be purchased by the Investor at the Closing shall be $205,000
(the “Purchase Price”). The Note will be issued with an original issue discount of approximately 33.33%.
The Investor shall pay approximately $0.6666 for each $1.00 of principal amount of the Note to be purchased at the Closing. At
the Closing, the Investor shall fund the Purchase Price by wire transfer of immediately available funds to the account specified
in writing by the Company prior to the date hereof.

3.                 
The Closing. Subject to the conditions set forth below, the purchase and sale of the Note shall take place at the
offices of Greenberg Traurig, LLP, The MetLife Building, 200

    	 

    	 

    

Park Avenue, New York, New York 10166,
on the date hereof (the “Closing” and the “Closing Date”). At the Closing,
the Company shall deliver to the Investor: (i) this Agreement duly executed by the Company, (ii) the Note in the Principal Amount
duly executed by the Company and registered in the name of the Investor and (iii) the Registration Rights Agreement duly executed
by the Company. At the Closing, the Investor shall deliver to the Company (i) this Agreement duly executed by the Investor and
(ii) the Registration Rights Agreement duly executed by the Investor.

4.                 
Closing Conditions; Certain Covenants.

4.1             
Conditions to the Investor’s Obligations. The obligation of the Investor to purchase the Note to be issued
to the Investor at the Closing is subject to the fulfillment, to the Investor’s reasonable satisfaction, prior to or at the
Closing, of each of the following conditions:

(a)               
Representations and Warranties. The representations and warranties of the Company contained in this Agreement shall
be true and correct in all material respects on the date hereof.

(b)              
Note. At the Closing, the Company shall have tendered to the Investor the Note.

(c)               
Registration Rights Agreement. The Company shall have duly executed and delivered the Registration Rights Agreement
to the Investor.

(d)              
No Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened
or proposed before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain substantial
damages in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

(e)               
Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents
and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the Investor, and the Investor
shall have received all such counterpart originals or certified or other copies of such documents as it may reasonably request.

4.2             
Conditions to the Company’s Obligations. The obligation of the Company to sell and issue the Note to the Investor
at the Closing is subject to the fulfillment, to the Company’s reasonable satisfaction, prior to or at the Closing, of each
of the following conditions:

(a)               
Representations and Warranties. The representations and warranties of the Investor contained in this Agreement shall
be true and correct in all material respects on the date hereof.

(b)              
Purchase Price. At the Closing, the Investor shall have tendered to the Company the Purchase Price (less the amounts
to be withheld pursuant to Section 10.12) by wire

    	2

    	 

    

transfer of immediately available funds
to the account specified in writing by the Company prior to the date hereof.

(c)               
Registration Rights Agreement. The Investor shall have duly executed and delivered the Registration Rights Agreement
to the Company.

(d)              
No Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened
or proposed before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial
damages in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

(e)               
Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents
and instruments incident to such transactions shall be satisfactory in substance and form to the Company and the Company shall
have received all such counterpart originals or certified or other copies of such documents as the Company may reasonably request.

4.3             
Securities Law Disclosure; Publicity. The Company shall (a) by 9:00 a.m. (New York City time) on the business day
immediately following the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby
and (b) issue a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby, and including
the Transaction Documents as exhibits thereto, within the time required by the 1934 Act. From and after the issuance of such press
release, the Company represents to the Investor that the Company shall have publicly disclosed all material, non-public information
delivered to the Investor by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees
or agents in connection with the transactions contemplated by the Transaction Documents. The Company shall afford the Investor
and its counsel with a reasonable opportunity to review and comment upon, shall consult with the Investor and its counsel on the
form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release,
Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor, its purchases hereunder
or any aspect of the Transaction Documents or the transactions contemplated thereby, prior to the issuance, filing or public disclosure
thereof, and the Company shall not issue, file or publicly disclose any such information to which the Investor shall object. For
the avoidance of doubt, the Company shall not be required to submit for review any such disclosure contained in periodic reports
filed with the Commission under the Exchange Act if it shall have previously provided the same disclosure for review in connection
with a previous filing.

4.4             
Legends. The Securities may only be disposed of in compliance with state and federal securities laws. In connection
with any transfer of Securities other than pursuant to an effective registration statement or Rule 144 under the 1933 Act (“Rule
144”), to the Company or to an affiliate of the Investor or in connection with a pledge, the Company may require
the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to
the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Securities under the 1933 Act. The Investor understands that the certificate
or other instrument representing the Note and, the stock certificates representing the

    	3

    	 

    

Conversion Shares, except as set forth
below, shall bear any legends as required by applicable state securities or “Blue Sky” laws in addition to a restrictive
legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

NEITHER THE
ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE]
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM
REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

The Company shall
use its reasonable best efforts to cause its transfer agent to remove the legend set forth above and to issue a certificate without
such legend to the holder of the Securities upon which it is stamped, or to issue to such holder by electronic delivery at the
applicable balance account at the Depository Trust Company (“DTC”), unless otherwise required by state
securities or “blue sky” laws, at such time as (i) such Securities are registered for resale under the 1933 Act, (ii)
in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, in a form
generally acceptable to the Company’s legal counsel, to the effect that such sale, assignment or transfer of the Securities
may be made without registration under the 1933 Act, or (iii) such holder provides the Company and its legal counsel with reasonable
assurance in writing that the Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A. In furtherance
of the foregoing, the Company agrees that, following the Effective Date or at such time as such legend is not required pursuant
to this Section 4.4, the Company shall, no later than three Trading Days following the delivery by the Investor to the Company
or the Company’s transfer agent of a certificate representing Conversion Shares issued with a restrictive legend (such third
Trading Day, the “Legend Removal Date”), either: (A) issue and deliver (or cause to be issued and delivered)
to the Investor a certificate representing such Conversion Shares that is free from all restrictive and other legends or (B) cause
the Company’s transfer agent to credit the Investor’s or its designee’s account at DTC through its Deposit/Withdrawal
at Custodian (DWAC) system with a number of shares of Common Stock equal to the number of Conversion Shares represented by the
certificate so delivered by the Investor. If the Company fails on or prior to the Legend Removal Date to either (i) issue and deliver
(or cause to be issued and delivered) to the Investor a certificate representing the Conversion Shares that is free from all restrictive
and other legends or (ii) cause the Company’s transfer agent to credit the balance account of the Investor or its designee
at DTC through its Deposit/Withdrawal at Custodian (DWAC) system with a number of shares of

    	4

    	 

    

Common Stock equal to the number of
Conversion Shares represented by the certificate delivered by the Investor pursuant hereto, then, in addition to all other remedies
available to the Investor, the Company shall pay in cash to the Investor on each day after the Legend Removal Date that the issuance
or credit of such shares is not timely effected an amount equal to 2.0% of the product of (A) the sum of the number of Conversion
Shares not issued to the Investor on a timely basis and to which the Investor is entitled and (B) the VWAP for the five Trading
Day period immediately preceding the Legend Removal Date. In addition to the foregoing, if the Company fails to so properly deliver
such unlegended certificates or so properly credit the account of the Investor or its designee at DTC by the Legend Removal Date,
and if on or after the Legend Removal Date the Investor purchases (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the Investor of shares of Common Stock that the Investor anticipated receiving from
the Company without any restrictive legend, then the Company shall, within three Trading Days after the Investor’s request,
pay cash to the Investor in an amount equal to the Investor’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver a certificate or credit the
Investor’s or its designee’s account at DTC for such shares of Common Stock shall terminate and such shares shall be
cancelled.

5.                 
Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure
Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and
warranties to the Investors:

5.1             
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Florida. The Company is duly qualified to transact business and is in good standing
in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

5.2             
Capitalization and Voting Rights. The authorized capital stock of the Company and the shares thereof issued and outstanding
were as set forth in the Public Reports as of the dates reflected therein. All of the outstanding shares of Common Stock have been
duly authorized and validly issued, and are fully paid and nonassessable. Except as set forth in the Public Reports, this Agreement
and the Registration Rights Agreement, there are no agreements or arrangements under which the Company is obligated to register
the sale of any securities under the Securities Act. Except as set forth in the Public Reports, no shares of Common Stock are entitled
to preemptive rights and there are no outstanding debt securities and no contracts, commitments, understandings, or arrangements
by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into or exchangeable for, any shares of capital stock of the Company other than those issued or granted in the ordinary course
of business pursuant to the Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer
restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth in the Public Reports,
the Company is not a party to, and it has no knowledge of, any agreement restricting the voting or transfer of any shares of the
capital stock of the Company. Except as set

    	5

    	 

    

forth in the Public Reports, the offer
and sale of all capital stock, convertible or exchangeable securities, rights, warrants or options of the Company issued prior
to the Closing Date complied with all applicable federal and state securities laws, and no stockholder has any right of rescission
or damages or any “put” or similar right with respect thereto that would have a Material Adverse Effect. Except as
set forth in the Public Reports, there are no securities or instruments containing anti-dilution or similar provisions that will
be triggered by the Note, this Agreement or the Registration Rights Agreement or the consummation of the transactions described
herein or therein.

5.3             
Authorization; Enforcement. All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement, the Note, the Registration Rights Agreement (the “Transaction
Documents”) and the performance of all obligations of the Company hereunder and thereunder, and the authorization
(or reservation for issuance), sale and issuance of the Note, and the Common Stock into which the Note is convertible or exercisable,
have been taken on or prior to the date hereof. Each of the Transaction Documents has been duly executed by the Company and, when
delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be limited by applicable law.

5.4             
Valid Issuance of the Conversion Shares; Reservation of Shares. The Note is duly authorized and, when issued and
paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, and free and clear of
all Liens imposed by the Company other than restrictions on transfer under this Agreement and under applicable state and federal
securities laws. The Conversion Shares when issued and delivered in accordance with the terms of this Agreement and the Note for
the consideration expressed herein and therein, will be duly and validly issued, fully paid and non-assessable and free and clear
of all Liens imposed by the Company other than restrictions on transfer under this Agreement and under applicable state and federal
securities laws. The Company has reserved from its duly authorized capital stock a sufficient number of shares of Common Stock
for issuance of the Conversion Shares.

5.5             
Offering. Subject to the truth and accuracy of the Investor’s representations set forth in Section 6 of this
Agreement, the offer and issuance of the Note, together with the Conversion Shares, as contemplated by this Agreement are exempt
from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and the
qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the Company nor
any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions.

5.6             
Public Reports. The Company is current in its filing obligations under the 1934 Act, including without limitation
as to its filings of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (collectively,
the “Public

    	6

    	 

    

Reports”). The
Public Reports do not contain any untrue statement of a material fact or omit to state any fact necessary to make any statement
therein not misleading. The financial statements included within the Public Reports for the fiscal year ended December 31, 2013
and for each quarterly period thereafter (the “Financial Statements”) have been prepared in accordance with
generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods indicated
and with each other, except that unaudited Financial Statements may not contain all footnote required by generally accepted accounting
principles. The Financial Statements fairly present, in all material respects, the financial condition and operating results of
the Company as of the dates, and for the periods, indicated therein, subject in the case of unaudited Financial Statements to
normal year-end audit adjustments.

5.7             
Compliance With Laws. The Company has not violated any law or any governmental regulation or requirement which violation
has had or would reasonably be expected to have a Material Adverse Effect on its business and the Company has not received written
notice of any such violation.

5.8             
Violations. The consummation of the transactions contemplated by the Transaction Documents and all other documents
and instruments required to be delivered in connection therewith will not result in or constitute any of the following: (a) a violation
of any provision of the certificate of incorporation, bylaws or other governing documents of the Company; (b) a violation of any
provisions of any applicable law or of any writ or decree of any court or governmental instrumentality; (c) a default or an event
that, with notice or lapse of time or both, would be a default, breach, or violation of a lease, license, promissory note, conditional
sales contract, commitment, indenture, mortgage, deed of trust, or other agreement, instrument, or arrangement to which the Company
is a party or by which the Company or its property is bound; (d) an event that would permit any party to terminate any agreement
or to accelerate the maturity of any indebtedness or other obligation of the Company; or (e) the creation or imposition of any
lien, pledge, option, security agreement, equity, claim, charge, encumbrance or other restriction or limitation on the capital
stock or on any of the properties or assets of the Company.

5.9             
Consents; Waivers. No consent, waiver, approval or authority of any nature, or other formal action, by any Person,
firm or corporation, or any agency, bureau or department of any government or any subdivision thereof, not already obtained, is
required in connection with the execution and delivery of the Transaction Documents by the Company or the consummation by the Company
of the transactions provided for herein and therein.

5.10         
Sarbanes-Oxley Act. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act
of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission
thereunder that are effective as of the date hereof.

5.11         
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against
or affecting the Company, the Common Stock or any of the Company’s officers or directors in their capacities as such.

    	7

    	 

    

5.12         
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial
statements included within the Public Reports, except as specifically disclosed in a subsequent Public Report filed prior to the
date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result
in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution
of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of
its capital stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, properties, operations, assets or financial condition, that would be required to be
disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been
publicly disclosed at least one Trading Day prior to the date that this representation is made.

5.13         
Intellectual Property. The Company has, or has rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights as described in the Public Reports as necessary or required for use in connection with their respective businesses
and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
The Company has not received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated
or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.
The Company has not received, since the date of the latest audited financial statements included within the Public Reports, a written
notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any
Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of
their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.

5.14         
Registration Rights. Other than the Investor or as set forth in the Public Reports, no Person has any right to cause
the Company to effect the registration under the 1933 Act of any securities of the Company.

5.15         
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither

    	8

    	 

    

it nor any other Person acting on its
behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute
material, non-public information. The Company understands and confirms that the Investor will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the
Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when
made, not misleading. The Company acknowledges and agrees that the Investor does not make nor has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 6 hereof.

5.16         
No Integrated Offering. Assuming the accuracy of the Investor’s representations and warranties set forth in
Section 6, neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the 1933 Act which would require
the registration of any such securities under the 1933 Act, or (ii) any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.

5.17         
Seniority. As of the Closing Date, no Indebtedness or other claim against the Company is senior to the Note in right
of payment, whether with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured
by purchase money security interests (which is senior only as to underlying assets covered thereby) and capital lease obligations
(which is senior only as to the property covered thereby).

5.18         
Bankruptcy Status; Indebtedness. The Company has no current intention or expectation to file for reorganization or
liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 5.18
sets forth as of the date hereof all outstanding secured and unsecured Indebtedness (as defined below) of the Company or any Subsidiary,
or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $25,000 (other than trade accounts payable incurred in
the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $25,000 due under leases required to be capitalized in
accordance with GAAP. The Company is not in default with respect to any Indebtedness.

    	9

    	 

    

5.19         
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for
soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s
placement agent in connection with the placement of the Securities.

5.20         
Acknowledgment Regarding Investor’s Purchase of Securities. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated
hereby and that the Investor is not (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate”
(as defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner”
of more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar
capacity) with respect to this Agreement and the transactions contemplated hereby, and any advice given by the Investor or any
of its representatives or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental
to the Investor’s purchase of the Securities. The Company further represents to the Investor that the Company’s decision
to enter into this Agreement, the Registration Rights Agreement, the Note and the other transaction documents to which it is a
party has been based solely on the independent evaluation by the Company and its representatives.

5.21         
No General Solicitation. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person acting on
its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D)
in connection with the offer or sale of the Securities.

5.22         
Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover
provision under its articles of incorporation, bylaws or other organizational documents, as amended to date, or the laws of the
jurisdiction of its incorporation or otherwise which is or could become applicable to the Investor as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Investor’s
ownership of the Securities. The Company and its board of directors have taken all necessary action, if any, in order to render
inapplicable any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of shares of
Common Stock or a change in control of the Company or any of its Subsidiaries.

5.23         
Foreign Corrupt Practices. Neither the Company nor any of its Subsidiaries nor any director, officer, agent, employee
or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf
of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution,

    	10

    	 

    

gift, entertainment or other unlawful
expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices
Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment
to any foreign or domestic government official or employee.

5.24         
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or
any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company
in its Public Reports and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

5.25         
Investment Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an
“investment company,” an affiliate of an “investment company,” a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for,
an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

5.26         
U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and
so long as any of the Securities are held by the Investor, shall become, a U.S. real property holding corporation within the meaning
of Section 897 of the Code, and the Company and each Subsidiary shall so certify upon the Investor’s request.

5.27         
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act
of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or
controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent (25%) or more of the total equity of a bank or any equity that is subject to the BHCA and to regulation by the Federal
Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or
policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

5.29         
Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, paragraph (i)
of Rule 144.

5.30         
Public Utility Holding Act. Neither the Company nor any of its Subsidiaries is a “holding company,” or
an “affiliate” of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

5.31         
Federal Power Act. Neither the Company nor any of its Subsidiaries is subject to regulation as a “public utility”
under the Federal Power Act, as amended.

5.32         
Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to
the best of the Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors,
employees, agents

    	11

    	 

    

or other representatives of the Company
or any of its Subsidiaries or any other business entity or enterprise with which the Company or any Subsidiary is or has been affiliated
or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services,
whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person or (b) to any political organization,
or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving
the direct or indirect use of funds of the Company or any of its Subsidiaries.

5.33         
Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the
USA Patriot Act of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without
limitation, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets
Control, including, without limitation, (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and
Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001));
and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.

5.34         
No Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of
the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is
defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer
Covered Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i)
to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification Event covered
by Rule 506(d)(2) or (d)(3) under the 1933 Act. The Company has exercised reasonable care to determine whether any Issuer Covered
Person is subject to a Disqualification Event.

6.                 
Representations and Warranties of the Investor. The Investor hereby represents, warrants and covenants that:

6.1             
Authorization. The Investor has full power and authority to enter into this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby and has taken all action necessary to authorize the execution
and delivery of this Agreement and the Registration Rights Agreement, the performance of its obligations hereunder and thereunder
and the consummation of the transactions contemplated hereby and thereby.

6.2             
No Public Sale or Distribution. The Investor is (i) acquiring the Note and (ii) upon conversion of the Note will
acquire the Conversion Shares for its own account, not as a nominee or agent, and not with a view towards, or for resale in connection
with, the public sale or distribution of any part thereof, except pursuant to sales registered or exempted under the 1933 Act.
The Investor is acquiring the Securities hereunder in the ordinary course of its business. The Investor does not presently have
any contract, agreement, undertaking, arrangement or understanding, directly or indirectly, with any individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization

    	12

    	 

    

and a government or any department or
agency thereof (a “Person”) to sell, transfer, pledge, assign or otherwise distribute any of the Securities.

6.3             
Accredited Investor Status; Investment Experience. The Investor is an “accredited investor” as that term
is defined in Rule 501(a) of Regulation D. The Investor can bear the economic risk of its investment in the Securities, and has
such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of an investment
in the Securities.

6.4             
Reliance on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance
on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions and
the eligibility of the Investor to acquire the Securities.

6.5             
Information. The Investor and its advisors, if any, have been furnished with all materials relating to the business,
finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested
by the Investor. The Investor and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither
such inquiries nor any other due diligence investigations conducted by the Investor or its advisors, if any, or its representatives
shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties contained
herein. The Investor understands that its investment in the Securities involves a high degree of risk. The Investor has sought
such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its
acquisition of the Securities. The Investor is relying solely on its own accounting, legal and tax advisors, and not on any statements
of the Company or any of its agents or representatives, for such accounting, legal and tax advice with respect to its acquisition
of the Securities and the transactions contemplated by this Agreement.

6.6             
No Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability
of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

6.7             
Validity; Enforcement; No Conflicts. This Agreement and each Transaction Document to which the Investor is a party
have been duly and validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, valid and
binding obligations of the Investor enforceable against the Investor in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies. The execution, delivery and performance by the Investor of this Agreement and each Transaction Document to which the
Investor is a party and the consummation by the Investor of the transactions contemplated hereby and thereby will not (i) result
in a violation of the

    	13

    	 

    

organizational documents of the Investor
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities or “Blue Sky” laws) applicable to the Investor, except in the case of clause (ii) above,
for such conflicts, defaults or rights which would not, individually or in the aggregate, reasonably be expected to have a material
adverse effect on the ability of the Investor to perform its obligations hereunder.

6.8             
Organization and Standing. The Investor is a limited liability company duly organized, validly existing and in good
standing under the laws of the State of New York.

7.                 
Use of Proceeds. The Investor acknowledges that the Company will use the proceeds received from the purchase of the
Note for, among other things, (i) costs and expenses relating to the sale of the Note to the Investor and (ii) general working
capital purposes.

8.                 
Rule 144 Availability; Public Information. At all times during the period commencing on the six (6) month anniversary
of the Closing Date and ending at such time that all of the Securities can be sold without the requirement to be in compliance
with Rule 144(c)(1) under the 1933 Act and otherwise without restriction or limitation pursuant to Rule 144, the Company shall
use its reasonable best efforts to ensure the availability of Rule 144 to the Investor with regard to the Conversion Shares, including
compliance with Rule 144(c)(1) under the 1933 Act. If, (i) at any time during the period commencing from the six (6) month anniversary
of the Closing Date and ending on the first anniversary of the Closing Date, the Company shall fail for any reason to satisfy the
current public information requirement under Rule 144(c) under the 1933 Act (a “Public Information Failure”),
or (ii) the Company shall fail to take such action as is reasonably requested by the Investor to enable the Investor to sell the
Conversion Shares pursuant to Rule 144 (including, without limitation, delivering all such legal opinions, consents, certificates,
resolutions and instructions to the Company’s transfer agent as may be reasonably requested from time to time by the Investor
and otherwise fully cooperate with Investor and Investor’s broker to effect such sale of securities pursuant to Rule 144),
then, in either case, in addition to the Investor’s other available remedies, the Company shall pay to a Investor, in cash,
as liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities,
an amount in cash equal to two percent (2.0%) of the aggregate Purchase Price of the Investor’s Securities on the day of
a Public Information Failure and on every thirtieth (30th) day (pro rated for periods totaling less than thirty days) thereafter
until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no
longer required for the Investor to transfer the Shares or the Warrant Shares pursuant to Rule 144. The payments to which the Investor
shall be entitled pursuant to this Section 8 are referred to herein as “Rule 144 Failure Payments.”
Rule 144 Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Rule 144 Failure
Payments are incurred and (ii) the third (3rd) Trading Day after the event or failure giving rise to the Rule 144 Failure Payments
is cured.

9.                 
Indemnification. In consideration of the Investor’s execution and delivery of this Agreement and acquiring
the Securities hereunder and in addition to all of the Company’s other obligations under this Agreement, the Registration
Rights Agreement and the Note, the Company

    	14

    	 

    

shall defend, protect, indemnify and
hold harmless the Investor and each holder of any Securities and all of their stockholders, partners, members, officers, directors,
employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification
hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation
or warranty made by the Company in this Agreement or the Registration Rights Agreement, (b) any breach of any covenant, agreement
or obligation of the Company contained in this Agreement or the Registration Rights Agreement or (c) any cause of action, suit
or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on
behalf of the Company or any Subsidiary) and arising out of or resulting from (i) the execution, delivery, performance or enforcement
of any of this Agreement, the Registration Rights Agreement or the Note, (ii) any transaction financed or to be financed in whole
or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) the status of the Investor or
holder of the Securities as an investor in the Company pursuant to the transactions contemplated by this Agreement. To the extent
that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Except as otherwise
set forth herein, the mechanics and procedures with respect to the rights and obligations under this Section 9 shall be the same
as those set forth in Section 6 of the Registration Rights Agreement. Notwithstanding anything to the contrary in this Section
9, the Company shall not be obligated to pay an Indemnitee any sums otherwise due under this Section 9 if the Company has already
paid the Indemnitee such sums for the same Indemnified Liabilities under Section 6 of the Registration Rights Agreement.

10.             
Miscellaneous

10.1         
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure
to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of the Securities).
Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective
successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.

10.2         
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed

    	15

    	 

    

herein, and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action
or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

10.3         
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.

10.4         
Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a)
upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day, (c) five (5) business days after having been sent by registered
or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to (a) in the case
of the Company, to Bioheart, Inc., 13794 NW 4th Street, Suite 212, Sunrise, Florida 33325, Telephone Number: (954) 835-1500,
Fax: (954) 845-9976, Attention: Mike Tomas, with a copy (which shall not constitute notice) to Joseph I. Emas, 1224 Washington
Avenue, Miami Beach, Florida 33139, Telephone: (305) 531-1174, or (b) in the case of the Investor, to Magna Equities II, LLC, a
New York limited liability company, c/o Magna, 5 Hanover Square, New York, NY 10004, Telephone Number: (347) 491-4240, Fax: (646)
737-9948, Attention: Marc Manuel, with a copy (which shall not constitute notice) to Greenberg Traurig, LLP, The MetLife Building,
200 Park Avenue, New York, New York 10166, Telephone Number (212) 801-9200, Fax: (212) 801-6400, Attention: Anthony J. Marsico,
Esq.

10.5         
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finders’ fee or
commission in connection with this transaction. The Company shall indemnify and hold harmless each Investor from any liability
for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such
liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

10.6         
Amendments and Waivers. No provision of this Agreement may be amended other than by a written instrument signed by
both parties hereto. No provision of this Agreement may be waived other than in a written instrument signed by the party against
whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of

    	16

    	 

    

any such power, right or privilege preclude
other or further exercises thereof or of any other right, power or privilege.

10.7         
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such
provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were
so excluded and shall be enforceable in accordance with its terms.

10.8         
Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties
and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as
specifically set forth herein or therein.

10.9         
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

10.10     
Interpretation. Unless the context of this Agreement clearly requires otherwise, (a) references to the plural include
the singular, the singular the plural, the part the whole, (b) references to any gender include all genders, (c) “including”
has the inclusive meaning frequently identified with the phrase “but not limited to” and (d) references to “hereunder”
or “herein” relate to this Agreement.

10.11     
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, the Investor and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained
in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

10.12     
Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this
Agreement; provided, however, that $30,000 (less $10,000 heretofore paid by the Company to the Investor) shall be withheld by the
Investor from the Purchase Price at the Closing as a non-accountable and non-refundable document preparation fee (the “Document
Preparation Fee”) in connection with the preparation, negotiation, execution and delivery of this Agreement, the
Registration Rights Agreement and the Note and legal due diligence of the Company, and shall be paid directly to the Investor’s
counsel on the Closing Date by wire transfer of immediately available funds. For the avoidance of doubt, the Document Preparation
Fee shall be non-refundable when paid. The Company shall pay all transfer agent fees (including, without limitation, any fees required
for same-day processing of any instruction letter delivered by the Company and any conversion or exercise notice delivered by the
Investor), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Investor.

10.13     
No Short Sales. So long as the Investor or its affiliates holds any Securities, neither the Investor nor any of its
affiliates nor any entity managed or controlled by

    	17

    	 

    

the Investor (collectively, the “Restricted
Persons” and each of the foregoing is referred to herein as a “Restricted Person”) shall,
directly or indirectly, engage in any Short Sales involving the Company’s securities; provided, that it is expressly understood
and agreed that, for purposes of determining whether a Short Sale shall be deemed to exist hereunder, a sale by a Restricted Person
of Common Stock shall not be deemed to be a “Short Sale” if executed at a time when such Restricted Person has an equivalent
offsetting long position in the Common Stock (or is deemed to have a long position hereunder or otherwise in accordance with Regulation
SHO under the 1934 Act); provided, further that no “Short Sale” shall be deemed to exist as a result of any failure
by the Company (or its agents) to deliver Conversion Shares upon conversion of the Note to any Restricted Person exercising the
Note. For purposes of determining whether a Restricted Person has an equivalent offsetting long position in the Common Stock, such
Restricted Person shall be deemed to hold “long” all Common Stock that is either (i) then owned by such Restricted
Person, if any, or (ii) then issuable to such Restricted Person as Conversion Shares pursuant to the terms of the Note held by
such Restricted Person, if any, (without regard to any limitations on conversion set forth in the Note and giving effect to any
conversion price adjustments that would take effect given only the passage of time). Notwithstanding the foregoing, nothing contained
herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person from selling “long”
(as defined under Rule 200 promulgated under Regulation SHO under the 1934 Act) the Securities or any other Common Stock then owned
by such Restricted Person.

10.14     
No Frustration. So long as the Investor or its affiliates hold any Securities, neither the Company nor any of its
affiliates or Subsidiaries, nor any of its or their respective officers, employees, directors, agents or other representatives,
will, without the prior written consent of the Investor (which consent may be withheld, delayed or conditioned in the Investor’s
sole discretion), effect, enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction
(or issue, amend or waive any security) that would or would reasonably be expected to restrict, delay, conflict with or impair
the ability or right of the Company to timely perform its obligations under this Agreement, the Registration Rights Agreement or
the Note, including, without limitation, the obligation of the Company to timely deliver Conversion Shares upon conversion of the
Note.

11.             
Additional Defined Terms. In addition to the terms defined elsewhere in this Agreement, the Registration Rights Agreement
or the Note, the following terms have the meanings set forth in this Section 11:

11.1         
“1934 Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder.

11.2         
“Commission” means the United States Securities and Exchange Commission.

11.3         
“Effective Date” means the earliest of the date that (a) the initial Registration Statement has
been declared effective by the Commission, (b) all of the Registrable Securities have been sold pursuant to Rule 144 or may be
sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required
under Rule 144 and without volume or manner-of-sale restrictions or (c) following the one year

    	18

    	 

    

anniversary of the Closing Date provided
that a holder of Registrable Securities is not an affiliate of the Company, all of the Registrable Securities may be sold pursuant
to an exemption from registration under Section 4(1) of the 1933 Act without volume or manner-of-sale restrictions.

11.4         
 “Liens” means a lien, charge pledge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction.

11.5         
“Material Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition
(financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document.

11.6         
“Registrable Securities” shall have the meaning set forth in the Registration Rights Agreement.

11.7         
“Short Sales” means “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the 1934 Act.

11.8         
“Subsidiary” or “Subsidiaries” means any corporation or other entity
of which at least a majority of the securities or other ownership interest having ordinary voting power for the election of directors
or other persons performing similar functions are at the time owned directly or indirectly by the Company and/or any of its other
Subsidiaries.

11.9         
“Trading Day” means any day on which the Common Stock is traded on the Trading Market, provided
that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on the Trading
Market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on the
Trading Market (or if the Trading Market does not designate in advance the closing time of trading on the Trading Market, then
during the hour ending at 4:00:00 p.m., New York City time) unless such day is otherwise designated as a Trading Day in writing
by the Investor.

11.10     
“Trading Market” means any of the following markets or exchanges on which the Common Stock is
listed or quoted for trading on the date in question: the OTC Bulletin Board, the NASDAQ Global Market, the NASDAQ Global Select
Market, the NASDAQ Capital Market, the New York Stock Exchange, NYSE Arca, the NYSE MKT, or the OTCQX Marketplace or the OTCQB
Marketplace operated by OTC Markets Group Inc. (or any successor to any of the foregoing).

11.11     
“VWAP” means the volume weighted average price (the aggregate sales price of all trades of Common
Stock during a Trading Day divided by the total number of shares of Common Stock traded during such Trading Day) of the Common
Stock during a Trading Day as reported by Bloomberg L.P. using the AQR function.

[SIGNATURES ON THE
FOLLOWING PAGE]

    	19

    	 

    

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

THE COMPANY

 

BIOHEART, INC.

 

 

	By: 	/s/ Mike Tomas
	 	Name: Mike Tomas
	 	Title: President & CEO

 

 

    	 

    	 

    

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

THE INVESTOR:

 

 

MAGNA EQUITIES II, LLC, a New York limited liability
company

 

	By:	/s/ Joshua Sason

Name: Joshua Sason

Title: Managing MemberExhibit 10.2 

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION
RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of October 7, 2014, between Bioheart,
Inc., a Florida corporation (the “Company”), and Magna Equities II, LLC, a New York limited liability
company (the “Investor”).

In connection with
the Securities Purchase Agreement, dated as of October 7, 2014, entered into by the Company and the Investor (the “Securities
Purchase Agreement”), the Company has agreed, upon the terms and subject to the conditions of the Securities Purchase
Agreement, to issue and sell to the Investor a promissory note of the Company (the “Note”), which will,
among other things, be convertible into shares of the Company’s common stock, $0.001 par value per share (the “Common
Stock”) to the Investor (as converted, the “Conversion Shares”) in accordance with the
terms of the Note.

To induce the Investor
to consummate the transactions contemplated by the Securities Purchase Agreement, the Company has agreed to provide certain registration
rights under the 1933 Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively,
the “1933 Act”), and applicable state securities laws.

The Company and
the Investor hereby agrees as follows:

Section
1.    Definitions. Capitalized terms
used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings given such
terms in the Securities Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the SEC pursuant to the 1933 Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements
to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated
by reference in such Prospectus.

“Effectiveness
Deadline” means, (i) with respect to the Initial Registration Statement required to be filed hereunder, the earlier
of (A) the 120th calendar day after the date of hereof in the event that such Registration Statement is subject to a
limited or full review by the SEC and (B) the fifth Trading Day after the date the Company is

    	 

    	 

    

notified (orally or in writing,
whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review,
and (ii) with respect to any additional Registration Statements which may be required pursuant to Section 2, the earlier of (A)
the 90th calendar day following the date on which an additional Registration Statement is required to be filed hereunder
in the event that such Registration Statement is subject to a limited or full review by the SEC and (B) the fifth Trading Day after
the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will
not be reviewed or will not be subject to further review.

“Filing
Deadline” means, with respect to the Initial Registration Statement required hereunder, the 45th calendar
day after the date of hereof, and, with respect to any additional Registration Statements which may be required pursuant to Section
2, the earliest practical date on which the Company is permitted to file such additional Registration Statement related to the
Registrable Securities (taking into account any Staff position with respect to date on which the Staff will permit such additional
Registration Statement to be filed with the SEC).

“Registrable
Securities” means, as of any date of determination, (a) all Conversion Shares then issuable upon conversion in full
of the Note (assuming on such date the Note are converted in full without regard to any conversion limitations therein), and (b)
any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event
with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities
for so long as (x) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the
SEC under the 1933 Act and such Registrable Securities have been disposed of in accordance with such effective Registration Statement,
or (y) such Registrable Securities have been previously sold in accordance with Rule 144.

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2, including (in each
case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such
registration statement.

“Rule
144” means Rule 144 promulgated by the SEC pursuant to the 1933 Act, as such rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such rule.

“Rule
415” means Rule 415 promulgated by the SEC pursuant to the 1933 Act, as such Rule may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as
such Rule.

“SEC”
means the United States Securities and Exchange Commission.

    

    	2

    	 

    

Section
2. Registration Statement Requirements.

(a)               
The Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with
the SEC the Initial Registration Statement on Form S-1, or such other form reasonably acceptable to the Investor, covering the
resale by the Investor of all or such portion of the Registrable Securities (as determined on the date of such filing and the effective
date of such Registration Statement, as applicable) as permitted by the SEC (provided that the Company shall use diligent efforts
to advocate with the SEC for the registration of all of the Registrable Securities) pursuant to Rule 415. In no event shall the
Company include any securities other than Registrable Securities on any Registration Statement pursuant to this Section 2 without
the prior written consent of the Investor. The Company shall have such Initial Registration Statement, and each other Registration
Statement required to be filed pursuant to the terms hereof, declared effective by the SEC as soon as practicable, but in no event
later than the applicable Effectiveness Deadline. If at any time all Registrable Securities are not covered by the Initial Registration
Statement filed pursuant to this Section 2, the Company shall file with the SEC one or more additional Registration Statements
so as to cover all of the Registrable Securities not covered by the Initial Registration Statement, in each case, as soon as practicable
(taking into account any Staff position with respect to date on which the Staff will permit such additional Registration Statement(s)
to be filed with the SEC), but in no event later than the applicable Filing Deadline for such additional Registration Statement(s).
By 9:30 a.m. New York time on the Business Day following the effective date of each Registration Statement filed in accordance
herewith, the Company shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in
connection with sales pursuant to such Initial Registration Statement.

(b)              
If the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering pursuant
to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such
Registration Statement to become effective and be used for resales by the Investor on a delayed or continuous basis under Rule
415 at then-prevailing market prices (and not fixed prices) (or as otherwise may be reasonably acceptable to the Investor), or
if after the filing of the Initial Registration Statement with the SEC pursuant to this Section 2, the Company is otherwise required
by the Staff or the SEC to reduce the number of Registrable Securities included in such Initial Registration Statement, then the
Company shall reduce the number of Registrable Securities to be included in such Initial Registration Statement (with the prior
consent, not to be unreasonably withheld, of the Investor as to the specific Registrable Securities to be removed therefrom) until
such time as the Staff and the SEC shall so permit such Registration Statement to become effective and be used as aforesaid. Notwithstanding
anything in this Agreement to the contrary, if after giving effect to the actions referred to in the immediately preceding sentence,
the Staff or the SEC does not permit such Registration Statement to become effective and be used for resales by the Investor on
a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices) (or as otherwise may be reasonably
acceptable to the Investor), the Company shall not request acceleration of the effective date of such Registration Statement, the
Company shall promptly (but in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant to
Rule 477 under the 1933 Act, and the Effectiveness Deadline shall automatically be deemed to have elapsed with respect to such
Registration Statement at such time as the Staff or the SEC has made a final and non-appealable determination that the SEC will
not permit such

    	3

    	 

    

Registration Statement to be so utilized
(unless prior to such time the Company and the Investor have received assurances from the Staff or the SEC reasonably acceptable
to the Investor that a new Registration Statement filed by the Company with the SEC promptly thereafter may be so utilized). In
the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall file additional Registration
Statements as permitted by the Staff or the SEC in accordance with this Section 2 until such time as all Registrable Securities
have been included in Registration Statements that have been declared effective and the prospectus contained therein is available
for use by the Investor.

(c)               
In addition, in the event that the Staff or the SEC requires the Investor seeking to resell securities under a Registration
Statement filed pursuant to this Agreement to be specifically identified as an “underwriter” in order to
permit such Registration Statement to become effective, and the Investor does not consent to being so named as an underwriter in
such Registration Statement, then, in each such case, the Company shall reduce the total number of Registrable Securities
to be registered on behalf of the Investor, until such time as the Staff or the SEC does not require such identification
or until the Investor accepts such identification and the manner thereof. If notwithstanding any such reduction, the Staff or the
SEC still requires that the Investor be specifically identified as an “underwriter” in order to permit such Registration
Statement to be declared effect, the Investor may, at its option, elect to have no Registrable Securities of the Investor be included
in such Registration Statement.

Section
3.    Registration Procedures.

(a)               
If and whenever the Company is required by the provisions of Section 2 to effect the registration of any Registrable
Securities under the 1933 Act, the Company will, as expeditiously as possible:

		(i)	subject to the timelines provided in this Agreement, prepare and file the Registration Statement
with the SEC, with respect to such Registrable Securities and use its reasonable best efforts to cause such Registration Statement
to become and remain effective for the period of the distribution contemplated thereby (determined as herein provided), respond
as promptly as commercially practicable to any comments received from the SEC with respect to a Registration Statement or any amendment
thereto and file any pre-effective amendments with respect to a Registration Statement as promptly as reasonable possible, and
promptly provide to the Investor copies of all filings and SEC letters of comment (provided that the Company shall excise any information
contained therein which would constitute material non-public information regarding the Company or any subsidiary) and notify the
Investor (by telecopier or by e-mail address provided by the Investor) on or before the second business day thereafter that the
Company receives notice that (i) the SEC has no comments or no further comments on the registration statement, and (ii) the registration
statement has been declared effective;

		(ii)	prepare and file with the SEC such amendments and supplements to such Registration Statement and
the prospectus used in connection therewith as

    	4

    	 

    

may be necessary to keep such
Registration Statement effective and prepare and file with the SEC such additional Registration Statements as may be required hereunder
and to keep each additional Registration Statement effective;

		(iii)	furnish to the Investor such number of copies of the Registration Statement and the prospectus
included therein (including each preliminary prospectus) as the Investor reasonably may request in order to facilitate the public
sale or their disposition of the securities covered by such Registration Statement or make them electronically available;

		(iv)	use its reasonable best efforts to register or qualify the Registrable Securities covered by such
Registration Statement under the securities or “Blue Sky” laws of such jurisdictions as the Investor shall request
in writing, provided, however, that the Company shall not for any such purpose be required to qualify to transact business as a
foreign corporation in any jurisdiction where it is not so qualified or to consent to service of process in any such jurisdiction;

		(v)	if applicable, list the Registrable Securities covered by such Registration Statement with the
principal market or exchange on which the Common Stock is then listed;

		(vi)	promptly notify the Investor of the Company’s becoming aware that a prospectus relating thereto
is required to be delivered under the 1933 Act, of the happening of any event or passage of time of which the Company has knowledge
as a result of which the prospectus contained in such Registration Statement, as then in effect, includes an untrue statement of
a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing or the financial statements included therein ineligible for inclusion or
which becomes subject to a SEC, state or other governmental order suspending the effectiveness of the Registration Statement covering
any of the Registrable Securities; and

		(vii)	cooperate with any broker-dealer through which the Investor proposes to resell its Registrable
Securities in effecting a filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by the
Investor, and the Company shall pay the filing fee required by such filing within two (2) business days of request therefor

(b)              
The Investor hereby covenants that it will not sell any Registrable Securities pursuant to such prospectus during
the period commencing at the time at which the Company gives the Investor notice of the suspension of the use of such prospectus
in accordance with this Section 3(b) and ending at the time the Company gives the Investor notice that the Investor may thereafter
effect sales pursuant to the prospectus, or until the Company delivers to the Investor or files with the SEC an amended or supplemented
prospectus.

    

    	5

    	 

    

Section 4. Provision of Documents. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement
with respect to the Registrable Securities of the Investor that the Investor shall furnish to the Company such information regarding
itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it,
as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities and
shall execute such documents in connection with such registration as the Company may reasonably request.

Section
5.    Expenses. All expenses incurred
by the Company in complying with Section 2, including, without limitation, all registration and filing fees, printing expenses
(if required), fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including
reasonable counsel fees) incurred in connection with complying with state securities or “Blue Sky” laws, fees of the
Financial Industry Regulatory Authority, Inc. (“FINRA”) in connection with any filing with FINRA pursuant
to FINRA Rule 5110 that may be required to be made by any broker through which the Investor intends to make sales of Registrable
Securities, transfer taxes, and fees of transfer agents and registrars, are called “Registration Expenses.”
The Company will pay all Registration Expenses in connection with any Registration Statement described in Section 2.

Section
6.    Indemnification.

(a)In the event
any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted by
law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls the
Investor within the meaning of Section 15 of the 1933 Act or Section 20 of the Securities Exchange Act of 1934 Act, as amended
(the “1934 Act”) and each of the directors, officers, shareholders, members, partners, employees, agents,
advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
the lack of such title or any other title) of such controlling Persons (each, an “Investor Party” and
collectively, the “Investor Parties”), against any losses, obligations, claims, damages, liabilities,
contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’
fees, costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Claims”)
incurred in investigating, preparing or defending any action, claim, lawsuit, inquiry, proceeding, investigation or appeal taken
from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether
pending or threatened, whether or not an Investor Party is or may be a party thereto (“Indemnified Damages”),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in
respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration
Statement or any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under
the securities or other “Blue Sky” laws of any jurisdiction in which Registrable Securities are offered (“Blue
Sky Filing”), or the omission or alleged omission to state a material fact required to be stated therein or necessary
to make the

    	6

    	 

    

statements therein not misleading or
(ii) any untrue statement or alleged untrue statement of a material fact contained in any prospectus (as amended or supplemented)
or in any prospectus supplement or the omission or alleged omission to state therein any material fact necessary to make the statements
made therein, in light of the circumstances under which the statements therein were made, not misleading (the matters in the foregoing
clauses (i) and (ii) being, collectively, “Violations”). Subject to Section 6(c), the Company shall reimburse
the Investor Parties, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses
incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained
herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Investor Party arising
out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company
by such Investor Party for such Investor Party expressly for use in connection with the preparation of such Registration Statement,
prospectus or prospectus supplement or any such amendment thereof or supplement thereto; (ii) shall not be available to the Investor
to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the prospectus (as amended
or supplemented) made available by the Company (to the extent applicable), including, without limitation, a corrected prospectus,
if such prospectus (as amended or supplemented) or corrected prospectus was timely made available by the Company pursuant to Section
3 and then only if, and to the extent that, following the receipt of the corrected prospectus no grounds for such Claim would have
existed; and (iii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior
written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of an Investor Party and shall survive the transfer of any
of the Registrable Securities by the Investor pursuant to Section 8(f).

(b)In connection
with any Registration Statement in which the Investor is participating, the Investor agrees to indemnify, hold harmless and defend,
to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers
who signs the Registration Statement and each Person, if any, who controls the Company within the meaning of the 1933 Act or the
1934 Act (each, an “Company Party”), against any Claim or Indemnified Damages to which any of them may
become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are
based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance upon and
in conformity with written information relating to the Investor furnished to the Company by the Investor expressly for use in connection
with such Registration Statement; and, subject to Section 6(c) and the below provisos in this Section 6(b), the Investor will reimburse
a Company Party any legal or other expenses reasonably incurred by such Company Party in connection with investigating or defending
any such Claim; provided, however, the indemnity agreement contained in this Section 6(b) and the agreement with
respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is
effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld or delayed, provided
further that the Investor shall be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does
not exceed the net proceeds to the Investor as a result of the applicable sale of Registrable Securities pursuant to such Registration
Statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Company
Party and shall survive

    	7

    	 

    

the transfer of any of the Registrable
Securities by the Investor pursuant to Section 8(f).

(c)Promptly
after receipt by an Investor Party or Company Party (as the case may be) under this Section 6 of notice of the commencement of
any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Investor
Party or Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under
this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall
have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and such
Investor Party or Company Party (as the case may be); provided, however, an Investor Party or Company Party (as the
case may be) shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying
party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have
failed promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company
Party (as the case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any
impleaded parties) include both such Investor Party or Company Party (as the case may be) and the indemnifying party, and such
Investor Party or Company Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely to
exist if the same counsel were to represent such Investor Party or Company Party and the indemnifying party (in which case, if
such Investor Party or Company Party (as the case may be) notifies the indemnifying party in writing that it elects to employ separate
counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof
on behalf of the indemnified party and such counsel shall be at the expense of the indemnifying party, provided further that in
the case of clause (iii) above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than
one (1) separate legal counsel for all Investor Parties or Company Parties (as the case may be). The Company Party or Investor
Party (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense
of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available
to such Company Party or Investor Party (as the case may be) which relates to such action or Claim. The indemnifying party shall
keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as to the status of the defense
or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim
or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably
withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Company Party or
Investor Party (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does
not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Party or Investor Party (as
the case may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include
any admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately preceding sentence shall
apply to Sections 6(a) and 6(b) hereof. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated
to all rights of the Company Party or Investor Party (as the case may be) with respect to all third parties, firms or corporations
relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying

    	8

    	 

    

party within a reasonable time of the
commencement of any such action shall not relieve such indemnifying party of any liability to such Investor Party or Company Party
(as the case may be) under this Section 6, except to the extent that the indemnifying party is materially and adversely prejudiced
in its ability to defend such action.

(d)No Person
involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the 1933 Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale of Registrable
Securities who is not guilty of fraudulent misrepresentation.

(e)The indemnification
required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or Indemnified Damages are incurred; provided that the Investor shall promptly reimburse
the Company for all such payments to the extent a court of competent jurisdiction determines that any Investor Party was not entitled
to such payments.

(f)The indemnity
and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company Party
or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant
to the law; provided, however, that the Company shall not be obligated to pay an Investor Party for Indemnified Damages associated
with a particular Claim under this Section 6 if the Company has already paid such Investor Party such Indemnified Damages under
Section 9 of the Securities Purchase Agreement.

Section
7.    Contribution. To the extent any
indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution
with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided,
however: (i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification
under the fault standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities
which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with
such sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty
of fraudulent misrepresentation; and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the
amount of net proceeds received by such seller from the applicable sale of such Registrable Securities pursuant to such Registration
Statement. Notwithstanding the provisions of this Section 7, the Investor shall not be required to contribute, in the aggregate,
any amount in excess of the amount by which the net proceeds actually received by the Investor from the applicable sale of the
Registrable Securities subject to the Claim exceeds the amount of any damages that the Investor has otherwise been required to
pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue or alleged untrue statement or omission
or alleged omission.

    

    	9

    	 

    

Section
8. Miscellaneous.

(a)               
Remedies. In the event of a breach by the Company or by the Investor of any of their respective obligations
under this Agreement, the Investor or the Company, as the case may be, in addition to being entitled to exercise all rights granted
by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this
Agreement. Each of the Company and the Investor agrees that monetary damages would not provide adequate compensation for any losses
incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of
any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at
law would be adequate.

(b)              
Compliance. The Investor covenants and agrees that it will comply with the prospectus delivery requirements
of the 1933 Act as applicable to it or an exemption therefrom in connection with sales of Registrable Securities pursuant to a
Registration Statement.

(c)               
Piggy-Back Registrations. If, at any time prior to the six month anniversary of the date hereof, there is
not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and
file with the SEC a registration statement relating to an offering for its own account or the account of others under the 1933
Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then
equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity
securities issuable in connection with the Company’s stock option or other employee benefit plans, then the Company shall
deliver to the Investor a written notice of such determination and, if within fifteen days after the date of the delivery of such
notice, the Investor shall so request in writing, the Company shall include in such registration statement all or any part of such
Registrable Securities the Investor requests to be registered; provided, however, that the Company shall not be required to register
any Registrable Securities pursuant to this Section 8(c) that are the subject of a then effective Registration Statement.

(d)              
Amendments and Waivers. No provision of this Agreement may be (i) amended other than by a written instrument
signed by both parties hereto or (ii) waived other than in a written instrument signed by the party against whom enforcement of
such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party
in exercising such right or remedy, shall not operate as a waiver thereof.

(e)               
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be delivered as set forth in the Securities Purchase Agreement.

(f)               
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and
permitted assigns of each of the parties. The Company may not assign (except by merger) its rights or obligations hereunder without
the prior written consent of the Investor. The Investor may assign its rights hereunder if: (i) the Investor agrees in writing
with such transferee or assignee (as the case may be) to assign all or any portion of such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such

    	10

    	 

    

transfer or assignment (as the case
may be); (ii) the Company is, within a reasonable time after such transfer or assignment (as the case may be), furnished with written
notice of (a) the name and address of such transferee or assignee (as the case may be), and (b) the securities with respect to
which such registration rights are being transferred or assigned (as the case may be); (iii) immediately following such transfer
or assignment (as the case may be) the further disposition of such securities by such transferee or assignee (as the case may be)
is restricted under the 1933 Act or applicable state securities laws if so required; (iv) at or before the time the Company receives
the written notice contemplated by clause (ii) of this sentence such transferee or assignee (as the case may be) agrees in writing
with the Company to be bound by all of the provisions contained herein; (v) such transfer or assignment (as the case may be) shall
have been made in accordance with the applicable requirements of the Securities Purchase Agreement and the Note; and (vi) such
transfer or assignment (as the case may be) shall have been conducted in accordance with all applicable federal and state securities
laws. The term “Investor” in this Agreement shall also include all such transferees and assignees.

(g)              
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when
taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event
that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

(h)              
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be determined in accordance with the provisions of the Securities Purchase Agreement.

(i)                
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their reasonable best efforts to find and employ an alternative means to achieve the same or substantially the
same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including
any of such that may be hereafter declared invalid, illegal, void or unenforceable.

(j)                
Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement
and shall not be deemed to limit or affect any of the provisions hereof.

(Signature Pages Follow)

    	11

    	 

    

IN WITNESS WHEREOF,
the parties have executed this Registration Rights Agreement as of the date first written above.

 

BIOHEART,
INC.

	By:	/s/ Mike Tomas
	 	Name: Mike
Tomas
	 	Title: President
& CEO

    	 

    	 

    

IN WITNESS WHEREOF,
the parties have executed this Registration Rights Agreement as of the date first written above.

 

Magna Equities II, LLC, a
New York Limited Liability Company

	By:	 /s/ Joshua Sason
	 	Name: Joshua
Sason
	 	Title: Managing
Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]